UnknownPhase 4

Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy

Taiwan120 participantsStarted 2011-06

Plain-language summary

Compare efficacy and safety of 10-day triple therapy (rabeprazole, clarithromycin and amoxicillin) plus N-acetylcystein versus 10-day concomitant therapy (rabeprazole, clarithromycin, amoxicillin and metronidazole) for re-eradication for gastric Helicobacter pylori infection.

Who can participate

Age range20 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient after treatment for Helicobacter pylori eradication. * Still clinically with evidence of gastric Helicobacter pylori infection. Exclusion Criteria: * woman in breast feeding or pregnancy. * allergy to drugs used in study. * never treated for H. pylori. * intolerance to fructose, lactose. * patients with hematologic, brain or spinal disorders. * patients under 20 years old. * patients with malignancy or with decompensated function of vital organs.

What they're measuring

Re-eradication rate

Timeframe: 4 weeks after complete use of drug for treatment

Trial details

NCT IDNCT01572597

SponsorBuddhist Tzu Chi General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-12

Contact for this trial

Ming-Cheh CHEN, M.D.

+886-910-521003 MingCheh_chen@tzuchi.com.tw

View on ClinicalTrials.gov More Bacterial Infection Due to Helicobacter Pylori (H. Pylori) trials